Biomerica, Inc. logo

Biomerica, Inc.

BMRA

NASDAQHealthcareMedical - Devices

Previous close

$1.61

+$0.025 · +1.58%

Aug 21, 4:00 PM ET

BMRA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

36

Expensive

Momentum

19

Strong Down

Sentiment

53

Mixed

Risk resilience

38

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Zackary S. Irani
Listed since
Sep 7, 1984
Employees
54

Market position

Day range

Current $1.61

52-week range

Current $1.61

Open
$1.575
Previous close
$1.585
Volume
9.88K
0.72× average
Average volume
13.67K
Average daily volume
Market cap
4.98M USD
Beta
0.31
Market reference 1
50-day average
$1.6816
-4.26% below average
200-day average
$2.1476
-25.03% below average

Financials

Financial snapshot

Latest / TTM

Financial health

Altman Z-score
-15.39
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends31%-30%-90%-150%Gross margin, FY2021: 5.09%Gross margin, FY2022: 15.78%Gross margin, FY2023: 8.35%Gross margin, FY2024: 11.28%Gross margin, FY2025: 9.38%Operating margin, FY2021: -104.18%Operating margin, FY2022: -24.03%Operating margin, FY2023: -135.29%Operating margin, FY2024: -117.58%Operating margin, FY2025: -96.72%Net margin, FY2021: -103.43%Net margin, FY2022: -24.01%Net margin, FY2023: -133.73%Net margin, FY2024: -110.40%Net margin, FY2025: -93.64%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 5.09%. Gross margin FY2022 15.78%. Gross margin FY2023 8.35%. Gross margin FY2024 11.28%. Gross margin FY2025 9.38%. Operating margin FY2021 -104.18%. Operating margin FY2022 -24.03%. Operating margin FY2023 -135.29%. Operating margin FY2024 -117.58%. Operating margin FY2025 -96.72%. Net margin FY2021 -103.43%. Net margin FY2022 -24.01%. Net margin FY2023 -133.73%. Net margin FY2024 -110.40%. Net margin FY2025 -93.64%.

Income trends

Revenue

5.31M USD-1.92%

Operating income

−5.14M USD+19.32%

Net income

−4.97M USD+16.81%
Income trends across reported periods21.51M USD10.96M USD411.64K USD−10.14M USDRevenue, FY2021: 7.2M USDRevenue, FY2022: 18.87M USDRevenue, FY2023: 5.34M USDRevenue, FY2024: 5.42M USDRevenue, FY2025: 5.31M USDOperating income, FY2021: −7.5M USDOperating income, FY2022: −4.53M USDOperating income, FY2023: −7.22M USDOperating income, FY2024: −6.37M USDOperating income, FY2025: −5.14M USDNet income, FY2021: −7.45M USDNet income, FY2022: −4.53M USDNet income, FY2023: −7.14M USDNet income, FY2024: −5.98M USDNet income, FY2025: −4.97M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 7.2M USD. Revenue FY2022 18.87M USD. Revenue FY2023 5.34M USD. Revenue FY2024 5.42M USD. Revenue FY2025 5.31M USD. Operating income FY2021 −7.5M USD. Operating income FY2022 −4.53M USD. Operating income FY2023 −7.22M USD. Operating income FY2024 −6.37M USD. Operating income FY2025 −5.14M USD. Net income FY2021 −7.45M USD. Net income FY2022 −4.53M USD. Net income FY2023 −7.14M USD. Net income FY2024 −5.98M USD. Net income FY2025 −4.97M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue5.31M USD5.42M USD5.34M USD18.87M USD7.2M USD
Cost of goods sold4.81M USD4.8M USD4.89M USD15.89M USD6.83M USD
Gross profit498K USD611K USD446K USD2.98M USD366.29K USD
Research and development1.02M USD1.49M USD1.58M USD1.81M USD2.19M USD
Selling, general, and administrative4.61M USD5.49M USD6.09M USD5.7M USD5.67M USD
Operating expenses5.64M USD6.98M USD7.67M USD7.51M USD7.87M USD
Interest income165K USD431K USD133K USD27K USD66.86K USD
Interest expense367 USD
Depreciation and amortization400K USD374K USD351K USD594.82K USD375.86K USD
Operating income−5.14M USD−6.37M USD−7.22M USD−4.53M USD−7.5M USD
Net income−4.97M USD−5.98M USD−7.14M USD−4.53M USD−7.45M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-2.16
FY2025
Latest fiscal-year revenue
5.31M USD
FY2025 · -1.92% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend-0.18-0.9-1.62-2.34FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend20.23M14.8M9.38M3.95MFY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

3 ratings

Limited analyst sample: 3 ratings. Interpret the distribution with caution.

Strong buy00%
Buy3100%
Hold00%
Sell00%
Strong sell00%

BMRA peers

ETFs holding BMRA

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research BMRA

research.disclaimer